Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Clinical trial NCT02393157 · RECRUITING

Trial details

NCT number: NCT02393157
Sponsor: New York Medical College
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-Hodgkin Lymphoma Burkitt Lymphoma Diffuse Large B-Cell Lymphoma Primary Mediastinal B-cell Lymphoma CD20+ Lymphoblastic Lymphoma Follicular Lymphoma, Grade III

Start date: 2015-08-21
Primary completion: 2026-12-01
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.